Epizyme (EPZM) to Present Data from EPZ-6438 Phase 1 at EORTC-AACR-NCI Symposium
Tweet Send to a Friend
Epizyme (Nasdaq: EPZM) announced, in conjunction with its development partner Eisai, that clinical data from the ongoing Phase 1 study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
